Drugs and natural bioactive products in modulation of inflammatory pathways in cancer: preclinical and clinical evidence of inflammasomes, cytokine networks, and macrophage polarization
- 7 March 2026
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 176, 116454
Abstract
No abstract availableKeywords
This publication has 282 references indexed in Scilit:
- Anticancer Molecular Mechanisms of Epigallocatechin Gallate: An Updated Review on Clinical TrialsFood Science & Nutrition, 2025
- The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLCCancer Medicine, 2025
- Perioperative COX2 and β‐adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trialCancer, 2020
- NOD‐like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLDHepatology, 2019
- Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 UpdateClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 UpdateClinical Pharmacology & Therapeutics, 2017
- Blockade of Cd47-Mediated Cathepsin S/Protease-Activated Receptor 2 Signaling Provides a Therapeutic Target for Hepatocellular CarcinomaHepatology, 2014
- Silibinin inhibits accumulation of myeloid‐derived suppressor cells and tumor growth of murine breast cancerCancer Medicine, 2014
- Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinomaCancer, 2012
- In vivo quercitrin anti‐inflammatory effect involves release of quercetin, which inhibits inflammation through down‐regulation of the NF‐κB pathwayEuropean Journal of Immunology, 2005